Investor Relations
Hello everybody,
As you may have heard by now, de Jong & Associates have been appointed to handle Investor Relations on behalf of Biolabs. We are extremely pleased to be part of a story that promises hope to millions.
de Jong & Associates is a professional Investor Relations firm that represents companies that have what we consider to be huge upside potential. We look for new technologies and products that we consider unique and far reaching.
We are reachable and responsive. Our contact particulars are as follows:
Ron de Jong
Tel: (877) 943-9065
Fax: (760) 943-7164
e-mail: biolabs@dejong.org
Please check our web site at dejong.org
To check our recent past performance on Investor Relations with regard to a Bulletin Board stock, enquire from investors on the Raging Bull site for HSNS ragingbull.com
or
MAREX.com (MRXX)
ragingbull.com
We do not engage in dialogue in chat rooms and on Message Boards, but do post information from time to time as circumstances require. Feel free to contact Ron telephonically at the above number for accurate and timely information.
Best Regards,
Jacques Terblanche
Chief Information Officer
de Jong & Associates
dejong.org
In order to comply with the provisions of section 17(b) of the Securities Act of 1933, which reads as follows (for the sake of completeness, section 17(b) is quoted in its entirety) it is hereby disclosed that:
' Use of interstate commerce for purpose of offering for sale. It shall be unlawful for any person, by the use of any means or instruments of transportation or communication in interstate commerce or by the use of the mails, to publish, give publicity to, or circulate any notice, circular, advertisement, newspaper, article, letter, investment service, or communication which, though not purporting to offer a security for sale, describes such security for a consideration received or to be received, directly or indirectly, from an issuer, underwriter, or dealer, without fully disclosing the receipt, whether past or prospective, of such consideration and the amount thereof. '
de Jong & Associates, in consideration for rendering its services as Investor Relations Consultants received or will receive from the issuer herein described, BioLabs, Incorporated, for a period of 1 year the sum of $5,000 per month and the option to purchase shares in the common stock of the company in the following amounts and at the following prices respectively: 140,000 at $3.875. |
